In recent years, researchers have shown that dichloroacetate, a PDK inhibitor, inhibits the inactivation of PDH, the gating enzyme for the oxidative phosphorylation of glucose, and as a result, inhibits aerobic glycolysis in tumor cells, reduces lactate production in the tumor microenvironment, and decreases the mitochondrial membrane potential, which in turn inhibits the growth of tumor cells and achieves tumor-suppressive effects (6). This evidence concerns the gene PDP1 and neoplasm.